Parkinson's disease (PD) is the second most common neurodegenerative disease. About
2% of the population above the age of 60 is affected by the disease. The pathological …

Over a period of more than 50 years, the symptomatic treatment of the motor symptoms of
Parkinson disease (PD) has been optimized using pharmacotherapy, deep brain …

Importance Urate elevation, despite associations with crystallopathic, cardiovascular, and
metabolic disorders, has been pursued as a potential disease-modifying strategy for …

Key points Parkinson's disease (PD) is a frequent neurodegenerative disease with a
premotor phase that lasts several years. Risk factors that have been linked to PD are …

As spaceflight becomes more common with commercial crews, blood-based measures of
crew health can guide both astronaut biomedicine and countermeasures. By profiling …

Neurological and psychiatric disorders are leading contributors to the global disease
burden, having a serious impact on the quality of life of both patients and their relatives …

Numerous studies have linked Parkinson′ s disease (PD) with low levels of uric acid (UA).
Low UA has been associated with the risk of developing PD, and its progression and …

This article summarizes (1) the recent achievements to further improve symptomatic therapy
of motor Parkinson's disease (PD) symptoms,(2) the still-few attempts to systematically …

Parkinson's disease (PD) is one of the most common neurodegenerative movement disorder
characterized by preferential loss of dopaminergic neurons of the substantia nigra pars …

Oxidative stress is considered one of the pathological mechanisms that cause Parkinson's
disease (PD), which has led to the investigation of several antioxidants molecules as a …